Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.67 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 3/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL541343 | 0.89 | HSD17B10 (0.76) | ATMTHRBTP53HSD17B10HTT | |
| SCHEMBL25411 | 0.86 | HSD17B10 (0.80) | ATMTHRBTP53HSD17B10HTT | |
| SCHEMBL14000400 | 0.84 | POLB (0.57) | ATMTHRBTP53HSD17B10HTT | |
| SCHEMBL148148 | 0.81 | KDM4E (0.58) | ATMTHRBTP53HSD17B10HTT | |
| SCHEMBL15033453 | 0.80 | ATM (0.58) | ATMTHRBTP53HSD17B10HTT | |
| SCHEMBL15020819 | 0.79 | HPGD (0.82) | ATMTP53HSD17B10HPGDALDH1A1 | |
| SCHEMBL13266757 | 0.79 | ALOX15 (0.64) | ATMTHRBTP53HSD17B10KMT2A | |
| SCHEMBL17480781 | 0.77 | ATM (0.71) | ATMTP53KMT2AHPGDLMNA | |
| SCHEMBL8366908 | 0.77 | ALDH1A1 (0.61) | ATMTHRBTP53HSD17B10HTT | |
| SCHEMBL31489 | 0.76 | RAB9A (0.72) | KMT2AKDM4ELMNAMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2610255-B1 | 1H-Benzo[d]imidazol-5-yl compounds and composition for treating inflammatory diseases | NEOPHARM CO LTD (KR) | 2016-02-24 | — | — | EP | disclosed |
| US-8809541-B2 | Heterocyclic compound, and composition for treating inflammatory diseases using same | NEOPHARM CO., LTD. (KR) | 2014-08-19 | — | — | US | disclosed |
| US-8809541-B2 | Heterocyclic compound, and composition for treating inflammatory diseases using same | NEOPHARM CO., LTD. (KR) | 2014-08-19 | — | — | US | disclosed |
| EP-2610255-A2 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | Neopharm Co., Ltd. (KR) | 2013-07-03 | — | — | EP | disclosed |
| US-20130158047-A1 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | NEOPHARM CO., LTD. (KR) | 2013-06-20 | — | — | US | disclosed |
| US-20130158047-A1 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | NEOPHARM CO., LTD. (KR) | 2013-06-20 | — | — | US | disclosed |
| WO-2012026766-A2 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | (주)네오팜 (KR) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158047-A1 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | F2RL1, F2R, F2RL3 | ATM 2915/4885THRB 3927/4885TP53 2452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.